Context Therapeutics ( (CNTX) ) has issued an announcement.
On April 9, 2025, Context Therapeutics announced the dosing of the first patient in its Phase 1 clinical trial for CT-95, a mesothelin x CD3 T cell engaging bispecific antibody. This marks Context’s second active clinical trial in 2025, following CTIM-76, and signifies progress in their mission to develop precision immunotherapies for solid tumors. The trial aims to evaluate the safety and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors, with initial data expected in mid-2026.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.
Context Therapeutics faces significant financial challenges with no revenue generation and persistent losses, weighing heavily on its stock score. The technical analysis shows a bearish trend, and valuation metrics indicate unprofitability. However, positive corporate events, such as advancements in their clinical pipeline and leadership changes, offer some potential for future growth. Overall, the company’s financial instability and current market position limit its stock attractiveness.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Context Therapeutics Inc. is a biopharmaceutical company focused on advancing T cell engaging bispecific antibodies for solid tumors. The company is developing an innovative portfolio of therapeutics, including CTIM-76, CT-95, and CT-202, targeting various cancer-related proteins. Context is headquartered in Philadelphia.
YTD Price Performance: -43.78%
Average Trading Volume: 188,525
Technical Sentiment Signal: Strong Buy
Current Market Cap: $54.27M
For a thorough assessment of CNTX stock, go to TipRanks’ Stock Analysis page.